Biocon Biologics recognized as Asia IP Elite for 2024 by IAM

Biocon Biologics Limited, a subsidiary of Biocon Limited, has once again been recognized as an Asia IP Elite for 2024 by IAM (Intellectual Asset Management), the world’s leading Intellectual Property (IP) publication.

This is the eighth consecutive year for Biocon and subsequently its subsidiary Biocon Biologics to make it to this prestigious list.

This prestigious accolade is awarded to a select group of Asia-based organisations that have demonstrated exceptional IP value creation and are considered leaders in the region.

In 2016, Biocon became the first and only Indian pharmaceutical company to be featured on the prestigious ASIA IP ELITE list for its robust IP management and consistent IP value creation.

Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said: “We are humbled to be recognized for the eighth consecutive year as an Asia IP Elite company by IAM, a testament to our commitment to innovation, intellectual property excellence, and patient-centric solutions.

“This accolade reinforces Biocon Biologics’ position as a leading global biosimilars company and underscores the critical role of our robust IP strategy in enabling affordable access to high quality biosimilar therapies worldwide. Our dedicated team continues to place IP at the core of our business, driving value creation and advancing healthcare solutions for millions of patients globally.”

This year, 93 entities from India, China, Japan, South Korea, Malaysia, Thailand, Taiwan, Australia, New Zealand, and Singapore featured on the Asia IP Elite 2024 list.